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Inflammatory monocyte gene 
expression: trait or state marker in bipolar 
disorder?
K. Becking1,2*†, B. C. M. Haarman2,3†, R. F. Riemersma van der Lek1,2, L. Grosse4, W. A. Nolen2, S. Claes5, 
H. A. Drexhage6 and R. A. Schoevers1,2
Abstract 
Background: This study aimed to examine whether inflammatory gene expression was a trait or a state marker in 
patients with bipolar disorder (BD).
Methods: 69 healthy controls (HC), 82 euthymic BD patients and 8 BD patients with a mood episode (7 depressed, 
1 manic) were included from the MOODINFLAME study. Six of the eight patients who had a mood episode were also 
investigated when they were euthymic (6 of the 82 euthymic patients). Of these participants the expression of 35 
inflammatory genes was determined in monocytes using quantitative-polymerase chain reaction, of which a total 
gene expression score was calculated as well as a gene expression score per sub-cluster.
Results: There were no significant differences in inflammatory monocyte gene expression between healthy controls 
and euthymic patients. Patients experiencing a mood episode, however, had a significantly higher total gene expres-
sion score (10.63 ± 2.58) compared to healthy controls (p = .004) and euthymic patients (p = .009), as well as when 
compared to their own scores when they were euthymic (p = .02). This applied in particular for the sub-cluster 1 gene 
expression score, but not for the sub-cluster 2 gene expression score.
Conclusions: Our study indicates that in BD inflammatory monocyte, gene expression is especially elevated while in 
a mood episode compared to being euthymic.
Keywords: Bipolar disorder, Gene expression, Mood episode, Trait, State
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Background
Disturbances in the immune system have frequently been 
reported in bipolar disorder (BD) (Leboyer et  al. 2012). 
Several meta-analyses found peripheral cytokines to be 
raised in patients compared to healthy controls (HC) 
(Modabbernia et al. 2013; Munkholm et al. 2013). How-
ever, the results are heterogeneous, with also studies 
reporting on normal (Guloksuz et al. 2010) or even lower 
cytokine levels (Boufidou et al. 2004) in BD compared to 
HC. This may be due to the fact that peripheral cytokines 
are strongly influenced by lifestyle and disease factors 
(O’Connor et  al. 2009). Focusing on the main cellular 
producers of these cytokines, such as circulating mono-
cytes and macrophages, may be a better approach to find 
stable markers for BD. Indeed, studies from our group 
focusing on gene expression of circulating monocytes 
found a discriminating pro-inflammatory gene expres-
sion in BD patients compared to HC (Drexhage et  al. 
2010; Padmos et al. 2008).
It remains unclear whether these immunological dis-
turbances are related to the mood state, or are a trait 
phenomenon. Most studies compared BD patients to 
HC, without differentiating between patients in differ-
ent mood states. The few available studies that exam-
ined immune disturbances across mood states found 
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significantly higher levels of peripheral inflammatory 
markers during a mood episode compared to euthymia 
(Barbosa et  al. 2014; Brietzke et  al. 2009; Cunha et  al. 
2008; Ortiz-Domínguez et  al. 2007; Tsai et  al. 2012). 
Regarding inflammatory gene expression, our original 
hypothesis prior to the study described below was that 
monocyte activity might be a diagnostic biomarker for 
BD and thus a trait factor. However, in further analysis 
of our previous study, we already found the expression 
of specific inflammatory genes to be higher in a small 
subsample of depressed versus euthymic patients and to 
a lesser extent in manic compared to euthymic patients 
(Padmos et  al. 2008). Furthermore, we reported a pos-
sible relation between a sub-cluster of genes and manic 
symptomatology (B.C.M. Haarman et al. 2014a) in BD.
In this report, we present the results of the MOOD-
INFLAME study, in which we compared euthymic BD 
patients with HC. Moreover, we present the results in of 
a small additional study in which BD patients were com-
pared both in a mood episode and when euthymic. Thus, 
our study aimed to examine whether inflammatory gene 
expression in monocytes is a trait or a state marker in BD.
Methods
Participants
Data were derived from the EU-funded MOODINFLAME 
study (“MOODINFLAME website” 2014) carried out to 
investigate possible inflammatory biomarkers to advance 
early diagnosis, treatment and prevention of mood dis-
orders. In the MOODINFLAME study, adult male and 
female subjects were included who were free of inflam-
mation-related symptoms including fever and current or 
recent infectious or inflammatory disease, uncontrolled 
systemic disease, uncontrolled metabolic disease or other 
significant uncontrolled somatic disorders known to 
affect mood. They did not use somatic medication known 
to affect mood or the immune system, such as corticos-
teroids, non-steroid anti-inflammatory drugs and statins. 
Female candidates who were pregnant or recently gave 
birth were excluded. The present study has been set up 
as a cross-sectional case–control study extended with a 
within-patient longitudinal design. Blood was analyzed of 
a sample of 159 adult participants recruited from two uni-
versity psychiatry clinics in Groningen (The Netherlands) 
and Leuven (Belgium). The sample consisted of 69 HC, 82 
euthymic BD patients (BD-Eu) and 8 BD patients with a 
mood episode (BD-Ep) (seven depressed, one manic). Six 
of the eight BD-Ep patients were also investigated when 
they were euthymic (6 of the 82 BD-Eu patients). Of these 
patients, one patient was first sampled in an episode and 
resampled after he was recovered, and the remaining five 
were first sampled being euthymic and resampled when 
they became ill again.
The study was approved by the ethical committees of 
the participating universities, and written informed con-
sent was obtained from all participants.
Assessments
DSM-IV BD diagnoses were established using the Mini-
International Neuropsychiatric Interview (MINI) (Lecru-
bier et  al. 1997; Sheenan et  al. 1998). The severity of 
depression was measured by the Inventory of Depressive 
Symptoms (IDS-C30) (Rush et  al. 1996) for BD patients 
in a face-to-face interview, for HCs with a self-report 
questionnaire (IDS-SR30). To determine the presence 
or intensity of manic symptomatology in patients, the 
Young Mania Rating Scale (YMRS) (Young et  al. 1978) 
was used. Mood states were defined as euthymic, manic 
or depressed, based on the MINI. BD-Eu patients were 
neither in a depressed nor (hypo-)manic episode at the 
time of measurement as indicated by an IDS-C30 score 
<22 and a YMRS score <12, respectively. The remaining 
clinical characteristics were obtained with the Patient 
Questionnaire from the former Stanley Foundation Bipo-
lar Network, including separate clinician and patient 
chapters covering a spectrum of clinical features (Lever-
ich et al. 2001). In the event of a mismatch of results from 
the MINI in relation to the Patient Questionnaire, diag-
noses were checked with the treating physician. Age of 
onset was defined as the age when the first mood episode 
occurred, and information on psychiatric medication was 
dichotomized.
Laboratory methods
To detect the expression of inflammatory genes of mono-
cytes, similar methods were used as described in the 
original study by Padmos et al. (2008). In short, RNA was 
isolated from purified monocytes and to obtain c-DNA 
for quantitative-polymerase chain reaction (q-PCR), 
1  μg of RNA was reverse transcribed using the cDNA 
high-capacity cDNA Reverse Transcription Kit (Applied 
Biosystems, Carlsbad, CA, USA). Then, relative to the 
housekeeping gene ABL1, the expression of ADM, 
ATF3, BCL2A1, BTG3, CCL2, CCL20, CCL7, CD9, 
CDC42, CXCL2, DHRS3, DUSP2, EMP1, EREG, FABP5, 
HSPA1A/HSPA1B, IL-1α, IL-1β, IL1R1, IL-6, IRAK2, 
MAFF, MAPK6, MXD1, NAB2, PDE4B, PTGS2, PTPN7, 
PTX3, RGCC32, SERPINB2, STX1A, THBD, TNF and 
TNFAIP3 was determined, using the comparative thresh-
old cycle (CT) method (Biosystems 2001). See Table 1 for 
the list of genes and corresponding proteins. Data were 
expressed as ΔCT values (values corrected to ABL1) and 
to control for site (Groningen and Leuven), fold change 
transformation was applied. By dividing the ΔCT scores 
of patients from Groningen by the mean of healthy con-
trols from Groningen and subsequently the scores of 
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patients from Leuven by the mean of healthy controls 
from Leuven, the relative gene expression was expressed 
as a fold change (FC) value (Biosystems 2001).
Gene score calculation
To obtain a simple measure for overall monocyte acti-
vation, we calculated a gene score from the expression 
levels as described by Grosse et  al. (2014). For each of 
the 35 genes, we determined a range in HC fold change 
gene expression, defined by the HC mean ±  1 standard 
deviation (SD). Then, we used this range as a standard to 
compare the gene expression across the different groups. 
A gene was considered up-regulated if the FC value was 
higher than the HC mean + 1 SD, and down-regulated if 
the FC-value was lower than the HC mean − 1 SD. Then, 
we calculated a total gene expression score by adding all 
up-regulated (+1), all down-regulated (−1) and all nor-
mally expressed (0) genes for each patient. This method 
proved to be valid, since the total gene scores showed 
highly significant correlations with the majority of the 
genes (Grosse et al. 2014).
Additionally, we calculated two separate sub-cluster 
gene scores, based on previous cluster analyses per-
formed by Drexhage et  al. (2010). The first sub-cluster 
consisted primarily of pro-inflammatory genes (see 
Table 1) and the second sub-cluster consisted of chemo-
taxis, adhesion, differentiation and motility genes (see 
Table 1).
Statistical analyses
All data were analyzed with SPSS version 20.0 (SPSS, 
Chicago, IL, USA). Sample characteristics were com-
pared using Pearson’s Chi square and Fisher’s exact 
tests for dichotomous and categorical variables, and for 
continuous variables ANOVA and t tests were used. To 
compare inflammatory gene expression scores across 
HCs, euthymic patients, mood episode patients and 
within-patient analyses, ANOVA was used. Results were 
reported as mean  ±  standard error. Because only an 
overall inflammatory gene expression score was used, 
correction for multiple testing was not applied. As a set 
of sensitivity analyses, we repeated all analyses using 
ANCOVA controlling for sex, age and body mass index 
(BMI).
Results
Table  2 shows the sample characteristics of HC, BD-Eu 
patients and BD-Ep patients. Figure  1 shows the total 
inflammatory gene expression scores in these groups. 
We found no significant differences between HC 
(2.58 ± 0.88) and BP-Eu (3.48 ± 0.84), or BD-Ep patients 
when they were euthymic (1.17  ±  0.94) (all p  >  .44). 
However, BD-Ep patients had a significantly higher total 
gene expression score (10.63  ±  2.58) compared to HC 
(p =  .004) and BD-Eu patients (p =  .009) and compared 
to their own scores when they were euthymic (p = .020). 
For the means of sub-cluster 1 score, again no signifi-
cant differences were found between HC (1.13 ±  0.41), 
BD-Eu (1.59  ±  0.39) and BD-Ep patients when they 
were euthymic (0.50 ± 1.38) (all p > .40). BP-Ep patients 
(5.13 ± 1.20) again had a significantly higher sub-cluster 
Table 1 List of genes with corresponding proteins
Gene symbol Name of corresponding protein
Inflammation
 ATF3 Cyclic AMP-dependent transcription factor 3
 BCL2A1 B cell lymphoma-2-related protein A1
 CCL20 C–C chemokine ligand 20
 CXCL2 C–X–C chemokine ligand 2
 DUSP2 Dual specificity protein phosphatase 2
 EREG Epiregulin
 IL-1β Interleukin 1β
 IL-6 Interleukin 6
 PDE4B cAMP-specific 3′,5′-cyclic phosphodiesterase 4B
 PTGS2 Prostaglandin G/H synthase (cyclooxygenase)
 PTX3 Pentraxin-related protein 3
 TNF Tumor necrosis factor
 TNFAIP3 Tumor necrosis factor, alpha-induced protein 3
Chemotaxis/adhesion/differentiation/motility
 CCL2 C–C chemokine ligand 2
 CCL7 C–C chemokine ligand 7
 CDC42 Cell division control protein 42 homolog
 DHRS3 Short-chain dehydrogenase/reductase 3
 EMP1 Epithelial membrane protein 1
 MAPK6 Mitogen-activated protein kinase 6
 NAB2 Nerve growth factor-induced protein A-binding 
protein 2




 BTG3 BTG family, member 3
 CD9 Cluster of differentiation 9 antigen
 FABP5 Fatty acid-binding protein 5
 HSPA1/HSPA1B Heat shock 70 kDa protein 1
 IL-1α Interleukin 1α
 IL1R1 Interleukin 1 receptor, type 1
 IRAK2 Interleukin 1 receptor-associated kinase-like 2
 MAFF Musculoaponeurotic fibrosarcoma oncogene 
homolog F
 MXD1 MAD protein
 RGCC32 Regulator of cell cycle
 SERPINB2 Plasminogen activator inhibitor-2
 THBD Thrombomodulin
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Table 2 Characteristics of patients and healthy controls (N = 159)
Differences (italics values) were considered significant if p < .05
SD standard deviation, BMI body mass index, IDS Inventory of Depressive Symptoms, YMRS Young Mania Rating Scale, SSRI selective serotonin reuptake inhibitor
a Based on χ2 tests and Fisher’s exact tests for dichotomous and categorical variables, ANOVA tests when comparing age and BMI, and t tests when comparing 
continuous variables between euthymic and mood episode BD patients
Healthy controls (N = 69) Bipolar disorder (N = 90) pa
Euthymic (N = 82) Mood episode (N = 8)
Female, n (%) 39 (56.5) 41 (50.0) 5 (62.5) .63
Age, mean (SD) 44.7 (16.1) 43.1 (12.1) 41.8 (12.7) .72
BMI, mean (SD) 23.9 (3.2) 25.7 (4.2) 26.89 (4.2) .005
IDS score, mean (SD) 4.8 (3.4) 8.7 (8.0) 42.1 (14.1) <.001
Clinical characteristics
 YMRS score, mean (SD) – 1.3 (1.2) 4.7 (6.4) .001
 Bipolar I disorder, n (%) – 53 (64.4) 5 (62.5) .90
 Bipolar II disorder, n (%) – 29 (35.4) 3 (37.5)
 Age of onset, mean (SD) – 23.3 (9.6) 21.8 (9.1) .68
 Lifetime psychotic features, n (%) 26 (31.7) 2 (25.0) .70
 Psychotropic medication –
Melatonin – 1 (1.2) 2 (25.0) .02
SSRI – 4 (4.9) 1 (12.5) .38
Antipsychotics – 14 (17.1) 1 (12.5) .74
Lithium – 62 (75.6) 2 (25.0) .003
Benzodiazepines – 11 (13.4) 2 (25.0) .37
Antiepileptics – 22 (26.8) 2 (25.0) .91
Fig. 1 Total monocyte gene expression score of healthy controls, euthymic and mood episode BD patients (N = 159). HC healthy controls, BD 
bipolar disorder. Black lines represent mean and standard error of the mean per group. Lines connecting values from the BD-Eu and BD-Ep group 
represent the euthymic patients who were measured again when they had a mood episode
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1 score compared to healthy controls, BD-Eu patients and 
compared to their own scores when they were euthymic 
(p = .002, p = .006 and p = .01, respectively). The mean 
sub-cluster 2 scores of HC (0.74 ± 0.28), BD-Eu patients 
(0.59  ±  0.26), BD-Ep patients (2.0  ±  0.81) and BD-Ep 
patients when they were euthymic (0.17 ± 0.94) did not 
differ significantly between any of the groups (all p > .10). 
When repeating the analyses adjusted for sex, age and 
BMI, this resulted in essentially the same results.
Discussion
To our knowledge, the present study is the first to show 
an elevated inflammatory monocyte gene expression 
in BD patients when experiencing a mood episode, 
compared to both HC and euthymic BD patients. Fur-
thermore, BD-Ep patients had an increased inflamma-
tory gene expression than when they were euthymic. 
This indicates that inflammatory gene expression in BD 
is related to the mood state, rather than being a trait 
marker.
Our findings are supported by several other studies 
examining peripheral cytokines, where the highest levels 
of cytokines are found in BD patients with a mood epi-
sode, although findings in these studies were not equivo-
cal (Barbosa et al. 2014; Brietzke et al. 2009; Cunha et al. 
2008; Ortiz-Domínguez et  al. 2007; Tsai et  al. 2012). 
Serum levels of cytokines are known to follow a differ-
ent pattern than monocyte gene expression (Mesman 
et  al. 2014). Belonging to the same developmental line-
age as brain microglia, monocyte activation may be more 
directly related to psychopathology than circulating 
cytokines (Beumer et al. 2012; Haarman et al. 2014b).
Previous studies from our group in different samples 
examining inflammatory monocyte gene expression in 
relation to BD found specifically the sub-cluster 2 genes 
to be related to a mood episode (Drexhage et  al. 2010; 
Padmos et  al. 2008) or to severity of manic symptoms 
(Haarman et al. 2014a). Although in our study the scores 
were also higher in BD-Ep patients, we did not find a sig-
nificant difference in sub-cluster 2 gene score compared 
to HC or BD-Eu patients. This can probably be explained 
by the fact that we included only one manic patient, 
whereas in our previous studies more manic patients 
were included and that we used a total gene score calcu-
lation, whereas the previous studies examined the sepa-
rate genes. Since sub-cluster 2 genes are associated with 
adhesion, cell differentiation and cell shape changes and 
sub-cluster 1 consists of the classic pro-inflammatory 
genes, it seems that in our sample having a mood episode 
is specifically associated with activation of the inflamma-
tory response system.
Although our finding that an increased inflammatory 
gene expression is more likely to be a state than a trait 
phenomenon, the causality and time sequence of these 
associations are still difficult to interpret. Based on the 
present data, we cannot be sure whether an increase in 
inflammatory gene expression preceded the mood epi-
sode, or vice versa. In an earlier study, we showed that 
increased immune activation represented by peripheral 
markers preceded the onset of manic symptoms in MDD 
patients (Becking et  al. 2013). The only way to examine 
a clear causal role for immune activation in the develop-
ment of a mood episode is to measure euthymic patients 
multiple times prior, during and after a mood episode.
Our study has several limitations. First and most 
important, although the total sample consisted of 159 
persons, we had only few BP-Ep patients: seven patients 
with a depression and only one manic patient. Since we 
examined only one manic patient, it is difficult to draw 
conclusions about inflammatory gene expression in a 
manic state. However, because we found already signifi-
cant differences in this small group, we would encourage 
future studies to include more patients with a mood epi-
sode and also to assess patients repeatedly during both 
an episode and when euthymic. Second, all our patients 
were treated naturalistically, which resulted in a variety 
of medications known to influence inflammatory gene 
expression, including lithium, anticonvulsants, antipsy-
chotics and antidepressants (Haarman et al. 2014a; Pad-
mos et al. 2008; Rybakowski 2000; Tourjman 2012). Since 
these effects are typically suppressive in nature, medica-
tion may have obscured a real difference in inflamma-
tory gene expression between BD-Eu patients and HC. 
However, the BP-Ep patients demonstrating significantly 
increased gene expression compared to both HC and 
BD-Eu patients used approximately the same medica-
tions, suggesting a pathophysiological cause. Third, our 
selection of genes was based on the study of Padmos et al. 
(Padmos et al. 2008) which found these specific signature 
genes, possibly ruling out other important genes. Finally, 
our study only focused on inflammatory gene expression 
of monocytes, which make up around 2–8 % of the total 
white blood cell population and is still a peripheral meas-
urement. It would also be of interest to examine other 
parts of the peripheral immune system (e.g., leukocyte 
subsets), or more proximal factors such as microglial 
activation in the brain or cytokine concentrations in cer-
ebrospinal fluid.
Conclusions
In conclusion, our study showed that in BD patients the 
presence of a mood episode was associated with elevated 
inflammatory monocyte gene expression. This may imply 
that immune activation found in BD may occur in epi-
sodic patients and not in euthymic patients and can be 
detected in monocytes. Studies in peripheral cytokines 
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corroborate our findings; however, our results in gene 
expression need to be replicated in larger samples before 
a firm conclusion can be drawn.
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